Fill out the form below and we'll send your colleague an invitation to the "Enabling Continuous Bioprocessing With Multi-Column Chromatography" event. As biopharmaceutical manufacturers move toward ...

Creative Biolabs announces upgraded downstream services designed to bridge the gap between raw antibody expression and ...

The use of acidic MPAs (pH 2–4) is the default in pharmaceutical testing because they suppress silanol ionization (from Si-OH to Si-O -) and improve peak shape for basic drugs. However, highly ...

Narrow-moat-rated Repligen is a leading provider of bioprocessing solutions for companies that manufacture biologic drugs. Its business lines include advanced filtration and fluid management systems ...

As of Tuesday, February 24, Repligen Corporation’s RGEN share price has dipped by 6.43%, which has investors questioning if ...

Background/aims Posterior capsule opacification (PCO) is the most frequent long-term complication after cataract surgery, caused by proliferation of residual lens epithelial cells (LECs). Metformin, a ...

Explore the evolution of clinical proteomics in modern medicine. Discover how advanced protein analysis transforms biomarker ...

Repligen (NASDAQ:RGEN) management said the company capped 2025 with a “great finish,” posting fourth-quarter revenue of $198 million and full-year revenue of $738 million, while exceeding the high end ...

The Global Renal Biomarkers Market is driven by increasing chronic kidney disease cases and aging populations, necessitating improved diagnostic tools. Key opportunities include rising demand for ...

Every week, we ask readers to think like an advice columnist and submit their advice to a question Carolyn Hax hasn’t answered. She feels she’s “begging for my time,” but the letter writer is a ...

“I think the meeting was a 10 in the sense that we got along great.” That was President Trump’s rating — with 10 being the highest possible score, in case you were wondering — of his tete-a-tete with ...

The numbers are stark. In the 12 months through June, growth stocks returned 19.9%, while value stocks managed only 9.6%. Alas for value investors, the two previous years tell the same story. In 2023 ...